innohep- tinzaparin sodium injection United States - English - NLM (National Library of Medicine)

innohep- tinzaparin sodium injection

celgene corporation - tinzaparin sodium (unii: 3s182et3ua) (tinzaparin - unii:7uq7x4y489) - injection - 20000 [iu] in 1 ml - innohep® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. the safety and effectiveness of innohep® were established in hospitalized patients. innohep® is contraindicated in patients with active major bleeding, in patients with (or history of) heparin-induced thrombocytopenia, or in patients with hypersensitivity to tinzaparin sodium. innohep® is contraindicated in patients aged 90 years or older with creatinine clearance ≤ 60 ml/min. patients with known hypersensitivity to heparin, sulfites, benzyl alcohol, or pork products should not be treated with innohep®.